CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
年龄并非障碍：老年人群中的 CAR-T 治疗
英文原题：Age is No Barrier: CAR-T Therapy in Older Adults.
查看英文原题
Age is No Barrier: CAR-T Therapy in Older Adults.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去十年中，CAR-T（CAR-T）细胞已经彻底改变了血液系统恶性肿瘤的治疗。随着针对五种疾病在不同治疗场景下的六种不同产品问世，CAR-T 的使用有所增加，处方者的接受度也在不断扩大。这些疗法具有显著毒性，可能限制其适用于所有患者人群。在注册试验中，老年人仅作为整体的一部分被纳入，而针对老年年龄特有的风险可能未被明确阐述。本综述的目的是总结来自临床试验以及真实世界证据的数据，这些数据概述了CAR-T 在老年人中的安全性。由于大多数数据来自用于弥漫性大B细胞淋巴瘤的CD19 CAR-T，因此CAR-T 似乎可以安全地用于老年人。
展开英文摘要原文
In the last decade, chimeric antigen receptor-T (CAR-T) cells have revolutionized the treatment of hematological malignancies. With six different products for five diseases in various settings, CAR-T use has increased, and the comfort level of prescribers continues to expand. These therapies carry substantial toxicities that may limit their applicability to all patient populations.
In the registrational trials, older adults are represented as part of a whole and risks specific to older age may not be clearly outlined. The aim of this review is to summarize the data from clinical trials, as well as real-life evidence, that outline the safety of CAR-T in older adults. With most of the data coming from CD19 CAR-T for diffuse large B-cell lymphoma, it appears that CAR-T can be safely administered to older individuals.
论文信息
- 作者
- Maakaron JE、William BM
- 第一作者单位
- University of Minnesota, Minneapolis, MN, USA.United States
- 通讯作者单位
- OhioHealth Blood and Marrow Transplant Program, OhioHealth, 500 Thomas Lane; A3, Columbus, OH, 43214, USA. basemmwilliam@gmail.com.United States
- 文献类型
- 综述
- 期刊
- Drugs & aging2023 Aug
- 原文标识
- PubMed 37432595 · DOI 10.1007/s40266-023-01047-z